Yarrow Therapeutics Inc. has divulged antibody-drug conjugates comprising antibody or antigen binding fragments covalently linked to ecteinascidin derivatives through linkers reported to be useful for the treatment of cancer.

Reistone Biopharma Co. Ltd. has described phosphodiesterase PDE4B1 inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, acute respiratory distress syndrome, atopic dermatitis, overactive bladder, psoriasis, ulcerative colitis and urticaria, among others.

Scientists from Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have identified UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) (bacterial) inhibitors reported to be useful for the treatment gram-negative bacterial infections.

Chengdu Chipscreen Pharmaceutical Ltd. has discovered Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.

Researchers at the University of Bradford have prepared and tested duocarmycins reported to be useful for the treatment of cancer.

Otsuka Pharmaceutical Co. Ltd. has disclosed antibody-drug conjugates comprising humanized monoclonal antibody targeting syndecan-1 (SDC1; SYND1; CD138) covalently linked to anticancer and/or cytotoxic agents through linkers reported to be useful for the treatment of cancer.

Shanghai Zedeman Pharmaceutical Technology Co. Ltd. has identified aryl hydrocarbon receptor (AhR) agonists reported to be useful for the treatment of autoimmune disease, cancer, diabetes, eye disorders, viral infections, psoriasis, and inflammatory and neurological disorders, among others.

Zeno Management Inc. has divulged GTPase KRAS (mutant) inhibitors (particularly, KRAS (G12C mutant)) reported to be useful for the treatment of cancer.

Aligos Therapeutics Inc. has described programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of liver cancer (hepatocellular carcinoma) and hepatitis B.

Beijing Primegene Therapeutics Co. Ltd. has identified azacycloalkane compounds acting as rho kinase 1 (ROCK1; p160-ROCK) and/or rho-associated protein kinase 2 (ROCK 2) inhibitors reported to be useful for the treatment of asthma, cancer, insulin resistance, neurodegeneration, osteoporosis and renal failure.